IPH4502

September 16, 2026: Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) said its strategic partnership with Sobi for lacutamab in T-cell lymphoma has closed, triggering a $75 million upfront payment and starting the TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma; first patient is expected in Q1 2027. The study is intended to support an accelerated approval filing in Sézary syndrome and later full approvals in Sézary syndrome and mycosis fungoides. Innate is eligible for up to $40 million in near-term milestones, up to $465 million in further milestones, plus tiered double-digit royalties.

IPH4502 (Nectin-4 exatecan ADC): Phase 1 dose-escalation and backfill enrollment completed in July 2026 with 76 patients across Nectin-4-expressing tumors. The company reported preliminary anti-tumor activity, including objective responses in urothelial cancer after prior enfortumab vedotin, NSCLC, and HNSCC, with limited hematologic toxicity. Initial data will be presented at ENA 2026 on November 18, 2026.

Monalizumab: AstraZeneca-sponsored Phase 3 PACIFIC-9 in unresectable Stage III NSCLC has completed enrollment; readout is expected in H2 2026.

IPH5201: Ongoing Phase 2 MATISSE in resectable NSCLC reported a 27.5% overall pathological complete response rate at a pre-planned interim analysis presented at AACR 2026; enrollment continues in PD-L1 ≥1% patients.

Innate also completed a €30 million equity financing and said cash runway is expected through end-Q1 2028.